Search research articles
Contact Us
Filters
Showing results (41-50 of 108) with videos related to
Page
of 11
Sort By:
American Journal of Hematology
|
June 12, 2010
Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition
Giovanni Barosi, Elisabetta Gattoni, Paola Guglielmelli, et al.
Vascular Health and Risk Management
|
February 28, 2007
Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level
Daria Roccatagliata, Fausto Avanzini, Lara Monesi, et al.
Pulmonary Pharmacology & Therapeutics
|
March 7, 2017
Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: A sub-analysis of GISSI-HF trial
Andrea Rossi, Riccardo M Inciardi, Andrea Rossi, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)
|
October 28, 2014
Global cardiovascular risk evaluation: pattern of algorithm use and risk modification in 'real life'
Alessandro Filippi, Simona Giampaoli, Francesco Lapi, et al.
Nutrition Research (New York, N.Y.)
|
September 17, 2016
Red blood cell oleic acid levels reflect olive oil intake while omega-3 levels reflect fish intake and the use of omega-3 acid ethyl esters: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Heart Failure trial
William S Harris, Serge Masson, Simona Barlera, et al.
International Journal of Cardiology
|
December 3, 2014
Prognostic impact of metabolic syndrome in patients with chronic heart failure: data from GISSI-HF trial
Pasquale Perrone-Filardi, Gianluigi Savarese, Marco Scarano, et al.
European Journal of Heart Failure
|
August 2, 2012
Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI-HF trial
Maria Teresa La Rovere, Gian Domenico Pinna, Roberto Maestri, et al.
Blood
|
April 19, 2007
Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study
Monica Galli, Giovanna Borrelli, Eva Marie Jacobsen, et al.
International Journal of Cardiology
|
February 8, 2014
Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials
Gianluigi Savarese, Alessandra Dei Cas, Giuseppe Rosano, et al.
Cardiology
|
September 13, 2016
Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial
Marco Canepa, Pier Luigi Temporelli, Andrea Rossi, et al.
Page
of 11
Search research articles
Search
Showing results (41-50 of 108) with videos related to
Sort By:
Page
of 11
American Journal of Hematology
|
June 12, 2010
Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition
Giovanni Barosi, Elisabetta Gattoni, Paola Guglielmelli, et al.
Vascular Health and Risk Management
|
February 28, 2007
Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level
Daria Roccatagliata, Fausto Avanzini, Lara Monesi, et al.
Pulmonary Pharmacology & Therapeutics
|
March 7, 2017
Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: A sub-analysis of GISSI-HF trial
Andrea Rossi, Riccardo M Inciardi, Andrea Rossi, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)
|
October 28, 2014
Global cardiovascular risk evaluation: pattern of algorithm use and risk modification in 'real life'
Alessandro Filippi, Simona Giampaoli, Francesco Lapi, et al.
Nutrition Research (New York, N.Y.)
|
September 17, 2016
Red blood cell oleic acid levels reflect olive oil intake while omega-3 levels reflect fish intake and the use of omega-3 acid ethyl esters: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Heart Failure trial
William S Harris, Serge Masson, Simona Barlera, et al.
International Journal of Cardiology
|
December 3, 2014
Prognostic impact of metabolic syndrome in patients with chronic heart failure: data from GISSI-HF trial
Pasquale Perrone-Filardi, Gianluigi Savarese, Marco Scarano, et al.
European Journal of Heart Failure
|
August 2, 2012
Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI-HF trial
Maria Teresa La Rovere, Gian Domenico Pinna, Roberto Maestri, et al.
Blood
|
April 19, 2007
Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study
Monica Galli, Giovanna Borrelli, Eva Marie Jacobsen, et al.
International Journal of Cardiology
|
February 8, 2014
Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials
Gianluigi Savarese, Alessandra Dei Cas, Giuseppe Rosano, et al.
Cardiology
|
September 13, 2016
Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial
Marco Canepa, Pier Luigi Temporelli, Andrea Rossi, et al.
Page
of 11